Navigation Links
Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
Date:4/29/2011

SAN DIEGO, April 29, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced it plans to report first quarter 2011 financial results on Friday, May 6, 2011 before the open of the financial markets. The announcement will be followed by a conference call with the investment community at 8:00 a.m. PDT (11:00 a.m. EDT), which will be simultaneously broadcast over the Internet. Management will discuss the financial results and highlights for the first quarter of 2011 and provide a product pipeline update.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

To participate by telephone, please dial 877.407.8037 for domestic callers or 201.689.8037 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company's Web site at www.halozyme.com. Shortly after the call an audio replay will be available on Halozyme's Web site for seven days. A telephone replay will be available by dialing 877.660.6853 from the U.S., or 201.612.7415 for international callers and using account # 367 and ID # 371588.  

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug d
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
2. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
3. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
4. Halozyme Therapeutics Realigns Management
5. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
6. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
7. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
8. Halozyme Therapeutics Announces Public Offering of Common Stock
9. Halozyme Provides HYLENEX® Product Reintroduction Update
10. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
11. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , August 20, 2014 ... of Glenmark Pharmaceuticals Limited India (GPL), announces the ... a novel clinical development candidate, GBR 1302, a ... developed by the Glenmark Biologics Research Centre located ... GBR 1302 is based on Glenmark,s innovative BEAT ...
(Date:8/19/2014)... Tenn. , Aug. 19, 2014   ... provide its patient experience technology to ... Under the five-year agreement, CarePoint Health will deploy ... Bayonne Medical Center, Christ Hospital and Hoboken University ... offers a range of software solutions to help ...
(Date:8/19/2014)... 19, 2014 Talyst, a market leader in ... the 2014 NPPA Summer Conference in Las ... its 340B software products and services.   ... supplying over 400 customers with a variety of software ... including its latest solution, AutoSplit® Contract Pharmacy and 340B ...
Breaking Medicine Technology:Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2Talyst Exhibits at the NPPA Summer Conference 2
... Development of New Vaccines to Prevent Tuberculosis , ... ROCKVILLE, Md. , July 1 ... E. Connolly has been named President and Chief Executive Officer.  He ... Executive Vice President and General Manager of Wyeth Vaccines.  He will take ...
... , July 1 The refinements in ... the fifth generation Leksell Gamma Knife® Perfexion™ are radically ... and other brain disorders. With Perfexion, physicians are applying ... treating more non-malignant targets located in critical areas and ...
Cached Medicine Technology:Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO 2Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO 3Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO 4Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elekta's Leksell Gamma Knife Perfexion 2Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elekta's Leksell Gamma Knife Perfexion 3Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elekta's Leksell Gamma Knife Perfexion 4Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elekta's Leksell Gamma Knife Perfexion 5
(Date:8/20/2014)... By Barbara Bronson Gray ... News) -- Although it,s extremely rare, colds, flu and ... of elevated risk for stroke in children, a new study ... have a stroke in the United States, said Dr. Heather ... neurology and pediatrics at the University of California, San Francisco ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, ... long been an option, but a new study shows that ... most common reasons women didn,t undergo reconstruction was that they ... or they were focused on their cancer treatment," said lead ... Sloan Kettering Cancer Center, in New York City. Also ...
(Date:8/20/2014)... to treating kidney failure by removing waste products from ... who suddenly developed the condition, in an analysis led ... Medicine. , Their findings, published online in the journal ... method that is standardly used for people with sudden ... the patient. , "Our findings question the accepted notion ...
(Date:8/20/2014)... treating cancer - using Botox. A study presented in ... shows that cancer growth could be suppressed by ... to cancer stem cells. The approach thus treated the ... safe and efficient. The researchers have thus far tested ... on humans. , The nervous system is crucial in ...
(Date:8/20/2014)... A common approach to treating kidney failure by ... survival chances for people who suddenly developed the condition, ... University of Pittsburgh School of Medicine. , ... PLOS One , suggest acute hemodialysis, an aggressive method ... failure, may not provide a definitive benefit to the ...
Breaking Medicine News(10 mins):Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Treating gastric cancer -- with Botox 2Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2
... July 10 Life is unfair, the economy is out ... true these statements might be, your ability to bounce back ... In his refreshing new self-help book, "Controlling Your Future: Six ... ), Richard Norgaard shows readers how to achieve total ...
... , , , , MARIETTA, Ga., July ... business executives that the top healthcare cost drivers for employers ... online webinar, hosted by Source Media, showed that lost workplace ... costly to employers. The purpose of the webinar was to ...
... Recently, students attended ... Anatomy 200 module of their Massage Therapy program at CNI College prepared them for a ... focus in this module. , ... Orange, CA (PRWEB) July 10, 2009 -- Recently, students attended a lab at a local ...
... ... can keep playing after shoulder joint replacement , ... Keystone, CO (Vocus) July 10, 2009 -- Replacing a joint in any ... not being able to return to a sport or activity. However, a new study presented ...
... A ... Hospital. , ... 2009 -- A Washington County woman is recovering well today after undergoing a new, robot-assisted ... is one of just a handful of bariatric patients in the region to benefit from ...
... July 9 Amgen (Nasdaq: AMGN ) announced ... Henderson, Ph.D., to the Company,s Board. Dr. Henderson, 48, ... School , having been the Eastman Kodak LFM Professor of ... MIT ) Sloan School since 1999. She specializes in technology ...
Cached Medicine News:Health News:'Controlling Your Future: Six Steps To A Better Life': New Self-Help Book Teaches the Art of Self-discipline, Self-control 2Health News:Poll of Business Executives Shows Most Companies Not Aware of True Costs of Healthcare 2Health News:Poll of Business Executives Shows Most Companies Not Aware of True Costs of Healthcare 3Health News:Poll of Business Executives Shows Most Companies Not Aware of True Costs of Healthcare 4Health News:CNI College Massage Therapy Students Experience Plastination & Cadaver Lab 2Health News:Shoulder Surgery Doesn't Prevent Return to Sports, According to New Study presented at AOSSM Annual Meeting 2Health News:Canonsburg Woman Undergoes Robot-Assisted Weight Loss Procedure at AGH 2Health News:Canonsburg Woman Undergoes Robot-Assisted Weight Loss Procedure at AGH 3Health News:Canonsburg Woman Undergoes Robot-Assisted Weight Loss Procedure at AGH 4Health News:Amgen Appoints Rebecca M. Henderson to the Company's Board of Directors 2
Black elastomer. Smooth finish. Non-Sterile....
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Medicine Products: